It’s almost 10 years since the SPRINT trial changed the landscape of hypertension treatment, by showing that intensive antihypertensive treatment to a systolic target of 120 mm/Hg, compared to standard...
Mineralocorticoid receptor antagonists (MRA), such as spironolactone, have been recommended as one of the key treatments for people with heart failure with reduced ejection fraction (HFrEF) for more than...
One of the many exciting things about being in medicine for a long time is seeing how things change. It’s one of the things I love about science the most – the way knowledge builds incrementally, like...
Most of the changing, evidence-based guidance we talk about at NB Medical is iterative; it builds on what comes before, practice is altered, modified, but seldom completely reversed. When that happens,...